Wageningen, The Netherlands and Portland, Oregon, USA
July 28, 2015
Keygene N.V. and Floragenex Inc. announced today that they have entered into an extended license agreement around KeyGene’s Sequence Based Genotyping (SBG) technology. The agreement enables Floragenex to extend its SBG service offerings to include ddRAD-Seq in noncommercial and academic research across all species. The agreement further cements KeyGene’s SBG technology licensing portfolio and advances Floragenex’s position as a services leader in fractional genomic sequencing applications. Financial terms of the agreement were not disclosed.
“KeyGene is very pleased to strengthen its relationship with Floragenex through this extended SBG license agreement”, said Michiel van Eijk, CSO of KeyGene. “Floragenex’ expertise, professionalism and impressive track record with RAD-Seq across a wide range of genomes logically fit with a broader portfolio of SBG service offerings. This will accelerate the understanding of genetic variation in plants, animals and other organisms in a highly cost-efficient manner.”
“As one of the earliest companies to utilize next-gen DNA sequencing for genotyping studies, Floragenex is pleased to now offer clients additional capabilities around SBG and ddRAD-Seq”, said Rick Nipper, the President of Floragenex. “Our genomics team looks forward to providing support for SBG projects and continuing our strong tradition of assisting the research and life sciences community”.
About Floragenex
Oregon-based Floragenex is a privately owned biotechnology company providing innovative solutions for genomic analysis in human, plant and animal systems. Since 2007, Floragenex has delivered impact results in hundreds of genomics studies focused on answering fundamental questions in genetics, ecology, evolutionary biology and biomedical research. With multiple offices located on the US Pacific coast, Floragenex technologies permit investigation of genomes at unprecedented levels for academic, governmental and commercial researchers
worldwide.
About KeyGene
The crop innovation company KeyGene is a privately owned Ag Biotech company with a primary focus on crop innovation. KeyGene’s approach is to enable molecular genetics for the future of global agriculture. KeyGene supports its strategic partners with cutting edge breeding technologies, bioinformatics and plant-based trait platforms, with more than 135 employees from all over the world. KeyGene has sites in Wageningen, the Netherlands and in Rockville, USA.
Topics
Species
